Cancers, Vol. 11, Pages 1786: Therapeutic Inducers of Apoptosis in Ovarian Cancer
Cancers, Vol. 11, Pages 1786: Therapeutic Inducers of Apoptosis in Ovarian Cancer
Cancers doi: 10.3390/cancers11111786
Authors:
Mudra Binju
Monica Angelica Amaya-Padilla
Graeme Wan
Hendra Gunosewoyo
Yohan Suryo Rahmanto
Yu Yu
Ovarian cancers remain one of the most common causes of gynecologic cancer-related death in women worldwide. The standard treatment comprises platinum-based chemotherapy, and most tumors develop resistance to therapeutic drugs. One mechanism of developing drug resistance is alterations of molecules involved in apoptosis, ultimately assisting in the cells’ capability to evade death. Thus, there is a need to focus on identifying potential drugs that restore apoptosis in cancer cells. Here, we discuss the major inducers of apoptosis mediated through various mechanisms and their usefulness as potential future treatment options for ovarian cancer. Broadly, they can target the apoptotic pathways directly or affect apoptosis indirectly through major cancer-pathways in cells. The direct apoptotic targets include the Bcl-2 family of proteins and the inhibitor of apoptotic proteins (IAPs). However, indirect targets include processes related to homologous recombination DNA repair, micro-RNA, and p53 mutation. Besides, apoptosis inducers may also disturb major pathways converging into apoptotic signals including janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3), wingless-related integration site (Wnt)/&...
Source: Cancers - Category: Cancer & Oncology Authors: Mudra Binju Monica Angelica Amaya-Padilla Graeme Wan Hendra Gunosewoyo Yohan Suryo Rahmanto Yu Yu Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Epithelial Cancer | Gastroschisis Repair | Hendra Virus | Ovarian Cancer | Ovaries | Women